智翔金泰：GR1802注射液青少年季节性过敏性鼻炎适应症的临床试验申请获得批准

Group 1 - The core point of the article is that Zhixiang Jintai has received approval from the National Medical Products Administration for the clinical trial of its product GR1802 injection for adolescent seasonal allergic rhinitis [2] - Zhixiang Jintai's revenue composition for the year 2024 is reported to be 99.92% from the pharmaceutical manufacturing industry and 0.08% from other businesses [2]